The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells

Tamilla Nechiporuk, Stephen E. Kurtz, Olga Nikolova, Tingting Liu, Courtney L. Jones, Angelo D’alessandro, Rachel Culp-Hill, Amanda D’almeida, Sunil K. Joshi, Mara Rosenberg, Cristina E. Tognon, Alexey Danilov, Brian Druker, Bill Chang, Shannon McWeeney, Jeffrey Tyner

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

To study mechanisms underlying resistance to the BCL2 inhibitor venetoclax in acute myeloid leukemia (AML), we used a genome-wide CRISPR/Cas9 screen to identify gene knockouts resulting in drug resistance. We validated TP53, BAX, and PMAIP1 as genes whose inactivation results in venetoclax resistance in AML cell lines. Resistance to venetoclax resulted from an inability to execute apoptosis driven by BAX loss, decreased expression of BCL2, and/or reliance on alternative BCL2 family members such as BCL2L1. The resistance was accompanied by changes in mitochondrial homeostasis and cellular metabolism. Evaluation of TP53 knockout cells for sensitivities to a panel of small-molecule inhibitors revealed a gain of sensitivity to TRK inhibitors. We relate these observations to patient drug responses and gene expression in the Beat AML dataset. Our results implicate TP53, the apoptotic network, and mitochondrial functionality as drivers of venetoclax response in AML and suggest strategies to overcome resistance. SIGNIFICANCE: AML is challenging to treat due to its heterogeneity, and single-agent therapies have universally failed, prompting a need for innovative drug combinations. We used a genetic approach to identify genes whose inactivation contributes to drug resistance as a means of forming preferred drug combinations to improve AML treatment.

Original languageEnglish (US)
Pages (from-to)910-925
Number of pages16
JournalCancer discovery
Volume9
Issue number7
DOIs
StatePublished - Jul 1 2019

Fingerprint

Myeloid Cells
Acute Myeloid Leukemia
Gene Silencing
Drug Combinations
Drug Resistance
Clustered Regularly Interspaced Short Palindromic Repeats
Gene Knockout Techniques
Inhibition (Psychology)
Homeostasis
Genome
Apoptosis
Gene Expression
Cell Line
4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

Nechiporuk, T., Kurtz, S. E., Nikolova, O., Liu, T., Jones, C. L., D’alessandro, A., ... Tyner, J. (2019). The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer discovery, 9(7), 910-925. https://doi.org/10.1158/2159-8290.CD-19-0125

The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. / Nechiporuk, Tamilla; Kurtz, Stephen E.; Nikolova, Olga; Liu, Tingting; Jones, Courtney L.; D’alessandro, Angelo; Culp-Hill, Rachel; D’almeida, Amanda; Joshi, Sunil K.; Rosenberg, Mara; Tognon, Cristina E.; Danilov, Alexey; Druker, Brian; Chang, Bill; McWeeney, Shannon; Tyner, Jeffrey.

In: Cancer discovery, Vol. 9, No. 7, 01.07.2019, p. 910-925.

Research output: Contribution to journalArticle

Nechiporuk, T, Kurtz, SE, Nikolova, O, Liu, T, Jones, CL, D’alessandro, A, Culp-Hill, R, D’almeida, A, Joshi, SK, Rosenberg, M, Tognon, CE, Danilov, A, Druker, B, Chang, B, McWeeney, S & Tyner, J 2019, 'The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells', Cancer discovery, vol. 9, no. 7, pp. 910-925. https://doi.org/10.1158/2159-8290.CD-19-0125
Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D’alessandro A et al. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer discovery. 2019 Jul 1;9(7):910-925. https://doi.org/10.1158/2159-8290.CD-19-0125
Nechiporuk, Tamilla ; Kurtz, Stephen E. ; Nikolova, Olga ; Liu, Tingting ; Jones, Courtney L. ; D’alessandro, Angelo ; Culp-Hill, Rachel ; D’almeida, Amanda ; Joshi, Sunil K. ; Rosenberg, Mara ; Tognon, Cristina E. ; Danilov, Alexey ; Druker, Brian ; Chang, Bill ; McWeeney, Shannon ; Tyner, Jeffrey. / The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. In: Cancer discovery. 2019 ; Vol. 9, No. 7. pp. 910-925.
@article{5124c51e76bd40639b2cd4101338637e,
title = "The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells",
abstract = "To study mechanisms underlying resistance to the BCL2 inhibitor venetoclax in acute myeloid leukemia (AML), we used a genome-wide CRISPR/Cas9 screen to identify gene knockouts resulting in drug resistance. We validated TP53, BAX, and PMAIP1 as genes whose inactivation results in venetoclax resistance in AML cell lines. Resistance to venetoclax resulted from an inability to execute apoptosis driven by BAX loss, decreased expression of BCL2, and/or reliance on alternative BCL2 family members such as BCL2L1. The resistance was accompanied by changes in mitochondrial homeostasis and cellular metabolism. Evaluation of TP53 knockout cells for sensitivities to a panel of small-molecule inhibitors revealed a gain of sensitivity to TRK inhibitors. We relate these observations to patient drug responses and gene expression in the Beat AML dataset. Our results implicate TP53, the apoptotic network, and mitochondrial functionality as drivers of venetoclax response in AML and suggest strategies to overcome resistance. SIGNIFICANCE: AML is challenging to treat due to its heterogeneity, and single-agent therapies have universally failed, prompting a need for innovative drug combinations. We used a genetic approach to identify genes whose inactivation contributes to drug resistance as a means of forming preferred drug combinations to improve AML treatment.",
author = "Tamilla Nechiporuk and Kurtz, {Stephen E.} and Olga Nikolova and Tingting Liu and Jones, {Courtney L.} and Angelo D’alessandro and Rachel Culp-Hill and Amanda D’almeida and Joshi, {Sunil K.} and Mara Rosenberg and Tognon, {Cristina E.} and Alexey Danilov and Brian Druker and Bill Chang and Shannon McWeeney and Jeffrey Tyner",
year = "2019",
month = "7",
day = "1",
doi = "10.1158/2159-8290.CD-19-0125",
language = "English (US)",
volume = "9",
pages = "910--925",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells

AU - Nechiporuk, Tamilla

AU - Kurtz, Stephen E.

AU - Nikolova, Olga

AU - Liu, Tingting

AU - Jones, Courtney L.

AU - D’alessandro, Angelo

AU - Culp-Hill, Rachel

AU - D’almeida, Amanda

AU - Joshi, Sunil K.

AU - Rosenberg, Mara

AU - Tognon, Cristina E.

AU - Danilov, Alexey

AU - Druker, Brian

AU - Chang, Bill

AU - McWeeney, Shannon

AU - Tyner, Jeffrey

PY - 2019/7/1

Y1 - 2019/7/1

N2 - To study mechanisms underlying resistance to the BCL2 inhibitor venetoclax in acute myeloid leukemia (AML), we used a genome-wide CRISPR/Cas9 screen to identify gene knockouts resulting in drug resistance. We validated TP53, BAX, and PMAIP1 as genes whose inactivation results in venetoclax resistance in AML cell lines. Resistance to venetoclax resulted from an inability to execute apoptosis driven by BAX loss, decreased expression of BCL2, and/or reliance on alternative BCL2 family members such as BCL2L1. The resistance was accompanied by changes in mitochondrial homeostasis and cellular metabolism. Evaluation of TP53 knockout cells for sensitivities to a panel of small-molecule inhibitors revealed a gain of sensitivity to TRK inhibitors. We relate these observations to patient drug responses and gene expression in the Beat AML dataset. Our results implicate TP53, the apoptotic network, and mitochondrial functionality as drivers of venetoclax response in AML and suggest strategies to overcome resistance. SIGNIFICANCE: AML is challenging to treat due to its heterogeneity, and single-agent therapies have universally failed, prompting a need for innovative drug combinations. We used a genetic approach to identify genes whose inactivation contributes to drug resistance as a means of forming preferred drug combinations to improve AML treatment.

AB - To study mechanisms underlying resistance to the BCL2 inhibitor venetoclax in acute myeloid leukemia (AML), we used a genome-wide CRISPR/Cas9 screen to identify gene knockouts resulting in drug resistance. We validated TP53, BAX, and PMAIP1 as genes whose inactivation results in venetoclax resistance in AML cell lines. Resistance to venetoclax resulted from an inability to execute apoptosis driven by BAX loss, decreased expression of BCL2, and/or reliance on alternative BCL2 family members such as BCL2L1. The resistance was accompanied by changes in mitochondrial homeostasis and cellular metabolism. Evaluation of TP53 knockout cells for sensitivities to a panel of small-molecule inhibitors revealed a gain of sensitivity to TRK inhibitors. We relate these observations to patient drug responses and gene expression in the Beat AML dataset. Our results implicate TP53, the apoptotic network, and mitochondrial functionality as drivers of venetoclax response in AML and suggest strategies to overcome resistance. SIGNIFICANCE: AML is challenging to treat due to its heterogeneity, and single-agent therapies have universally failed, prompting a need for innovative drug combinations. We used a genetic approach to identify genes whose inactivation contributes to drug resistance as a means of forming preferred drug combinations to improve AML treatment.

UR - http://www.scopus.com/inward/record.url?scp=85069267133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069267133&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-19-0125

DO - 10.1158/2159-8290.CD-19-0125

M3 - Article

VL - 9

SP - 910

EP - 925

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 7

ER -